CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes

Michela Capello; Johannes F. Fahrmann; Mayrim V. Rios Perez; Jody V. Vykoukal; Ehsan Irajizad; Satyendra C. Tripathi; David Roife; Leonidas E. Bantis; Ya’an Kang; Deepali L. Kundnani; Hanwen Xu; Laura R. Prakash; James P. Long; Hiroyuki Katayama; Alia Fleury; Sammy Ferri-Borgogno; Dodge L. Baluya; Jennifer B. Dennison; Clemente Aguilar-Bonavides; Julian P. Casabar; Muge Celiktas; Kim-Anh Do; Oliver Fiehn; Anirban Maitra; Huamin Wang; Ziding Feng; Paul J. Chiao; Matthew H. Katz; Jason B. Fleming; Samir M. Hanash

Journal ArticleOPEN ACCESS

CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes

Capello M
Fahrmann J
Rios Perez M
et al.

JCO Precision Oncology (2020) (4) 426-436

DOI: 10.1200/po.19.00330

15Citations

30Readers

Abstract

PURPOSEThe combination chemotherapy of fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) has provided clinically meaningful improvement for pancreatic ductal adenocarcinoma (PDAC)....

Cite

CITATION STYLE

APA

Capello, M., Fahrmann, J. F., Rios Perez, M. V., Vykoukal, J. V., Irajizad, E., Tripathi, S. C., … Hanash, S. M. (2020). CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. JCO Precision Oncology, (4), 426–436. https://doi.org/10.1200/po.19.00330

CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes

Abstract

Cite

Register to see more suggestions